<DOC>
	<DOCNO>NCT00994643</DOCNO>
	<brief_summary>This study see maintenance therapy low dose interleukin-2 ( IL-2 ) rituximab delay prevent recurrences patient high risk Non-Hodgkin 's Lymphoma ( NHL ) . IL-2 naturally occur cytokine immune system may enhance activity know therapeutic agent rituximab , monoclonal antibody CD-20 , set NHL .</brief_summary>
	<brief_title>Safety Efficacy Study Immunotherapy With Rituximab Interleukin-2 Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Interleukin 2 ( IL-2 ) naturally circulate cytokine produce immune cell include T cell , dendritic cell thymic cell . IL-2 integral part T cell proliferation , autoimmunity self-tolerance . Low dose IL-2 study maintenance therapy follow autologous stem cell transplantation Non-Hodgkin 's Lymphoma . One early study show low dose IL-2 dose 3 million unit per m2 twice week one year increase activity absolute number natural killer ( NK ) cell type cytotoxic lymphocyte major component innate immune system . More importantly , dose IL-2 prolong time progression 9 patient residual disease autologous transplant induce sustained complete remission two patient . NK cell involve tumor kill via antibody dependent cell cytotoxicity , release cytotoxic granule cause direct tumor kill expression ligand trigger apoptosis program cell death . In study , change see regulatory T cell recently find exert inhibitory effect NK cell function hence limit NK cell 's ability exert anti-tumor effect.2,5 Because regulatory T cell NK cell express IL-2 receptor , high dose IL-2 administration ( 14MIU SQ thrice weekly ) would expand population cell may explain lack benefit see clinical study . At low dos 3MIU SQ twice weekly use earlier study , anticipate selective upregulation NK cell without effect regulatory T cell . Rituximab monoclonal antibody CD20 antigen express B cell lymphoma . It commonly use treatment B cell lymphoma either alone combination therapy . It use part initial treatment diagnosis well re-treatment lymphoma recur . It also study maintenance therapy relapse resistant follicular lymphoma show rituximab delayed disease progression compare group receive maintenance rituximab.11 The mechanism action rituximab include complement mediate cytotoxicity , antibody dependent cellular cytotoxicity , induction apoptosis sensitization cancer cell cytotoxic chemotherapy . Antibody dependent cellular cytotoxicity mediate NK cell , macrophage monocytes.13 The purpose study determine combination low dose IL-2 plus rituximab effective low dose IL-2 alone primary salvage therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm CD20 B cell nonHodgkin 's lymphoma Karnofsky performance status score 70 great ( ECOG performance status 0 2 ) . Age great 18 . Eligible patient start treatment D+30 D+100 end prior therapy Patients obtain complete remission induction chemotherapy salvage chemotherapy candidate autologous stem cell transplantation least partial remission autologous transplantation ( Stem cell collection , indicate , collect prior start therapy ) International Prognostic Index ( IPI ) * Follicular Lymphoma IPI ( FLIPI ) 3 Adequate organ function determine within 2 week prior study entry , define : Absolute neutrophil count ( ANC ) &gt; /=1000/mm3 , platelets &gt; /=100,000/mm3 , hemoglobin &gt; /=8 g/dl . Serum bilirubin &lt; 1.5 time ULN serum albumin &gt; 2.0 g/dl . If female , neither pregnant ( negative pregnancy test ) breastfeeding . If child bear potential ( &lt; one year postmenopausal ) , must agree practice effective method avoid pregnancy ( include oral implanted contraceptive , intrauterine device , condom , diaphragm spermicidal , cervical cap , abstinence sterile sex partner ) time inform consent sign . No concurrent active malignancy require treatment . Able render inform consent follow protocol requirement . CNS lymphoma Presence medical complication imply survival less three month . Prior IL2 therapy HIV Viral Hepatitis Karnofsky performance score less 70 . Pregnancy breastfeed . Unable unwilling utilize contraception childbearing potential . Severe cardiovascular disease within 12 month include myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attach , pulmonary embolism , life threaten arrhythmia , uncontrollable hypertension . Autoimmune disorder Concurrent immunosuppressive medication Concurrent systemic corticosteroid dos great replacement level Prior history intolerance rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>NHL</keyword>
	<keyword>Non Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
</DOC>